Guillaume P. Andrieu
@guillaumeandrieu.bsky.social
🩸Researcher exploring leukemia biology and treatment resistance |🔥Metabolism enthusiast | 🏥 Institut Necker and Hôpital Necker-Enfants Malades, INSERM | TRTH Class 2023
Happy to share our study published in @bloodjournal.bsky.social
🧬✂️🛑
We report that intragenic deletions of LEF1 generate a dominant-negative isoform and confer a targetable dependence on the Wnt/β-catenin pathway in T-ALL
Full story 👉: doi.org/10.1182/bloo...
🧬✂️🛑
We report that intragenic deletions of LEF1 generate a dominant-negative isoform and confer a targetable dependence on the Wnt/β-catenin pathway in T-ALL
Full story 👉: doi.org/10.1182/bloo...
LEF1 Intragenic Deletion Induces a Dominant-Negative isoform and unveils a Wnt/β3-Catenin Vulnerability in T-ALL
Key Points. LEF1 intragenic deletion is the most frequent LEF1 alteration in T-ALL and leads to a dominant-negative isoform.LEF1 intragenic deletion confer
doi.org
September 2, 2025 at 11:01 AM
Happy to share our study published in @bloodjournal.bsky.social
🧬✂️🛑
We report that intragenic deletions of LEF1 generate a dominant-negative isoform and confer a targetable dependence on the Wnt/β-catenin pathway in T-ALL
Full story 👉: doi.org/10.1182/bloo...
🧬✂️🛑
We report that intragenic deletions of LEF1 generate a dominant-negative isoform and confer a targetable dependence on the Wnt/β-catenin pathway in T-ALL
Full story 👉: doi.org/10.1182/bloo...
A fantastic program, insightful discussions, and exciting perspectives coming from the @helloeacr.bsky.social EACR Conference ‘Persister Cells’ on how to better identify, characterize and target drug-tolerant persister cells to leverage the treatment of bacterial infections and cancers.
March 19, 2025 at 4:10 PM
A fantastic program, insightful discussions, and exciting perspectives coming from the @helloeacr.bsky.social EACR Conference ‘Persister Cells’ on how to better identify, characterize and target drug-tolerant persister cells to leverage the treatment of bacterial infections and cancers.
📣Thrilled to share our recent study presenting a clinical-grade targeted therapy to exploit a metabolic vulnerability of PI3K-driven leukemia published in @naturecomms.bsky.social
🧵Key insights detailed below.
www.nature.com/articles/s41...
🧵Key insights detailed below.
www.nature.com/articles/s41...
A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer - Nature Communications
Deregulation of the Phosphoinositide 3-kinase (PI3K) pathway is associated with metabolic flexibility leading to cancer poor prognosis. Here, the authors show that targeting both glutamine degradation...
www.nature.com
March 19, 2025 at 4:02 PM
📣Thrilled to share our recent study presenting a clinical-grade targeted therapy to exploit a metabolic vulnerability of PI3K-driven leukemia published in @naturecomms.bsky.social
🧵Key insights detailed below.
www.nature.com/articles/s41...
🧵Key insights detailed below.
www.nature.com/articles/s41...